Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN: The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist. 2009, 14: 320-368. 10.1634/theoncologist.2008-0230.
Article
CAS
PubMed
Google Scholar
Dawood S, Broglio K, Buzdar AU, Hortobagyi GN, Giordano SH: Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol. 2010, 28: 92-98. 10.1200/JCO.2008.19.9844.
Article
CAS
PubMed
Google Scholar
Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987, 235: 177-182. 10.1126/science.3798106.
Article
CAS
PubMed
Google Scholar
Esteva FJ, Yu D, Hung M-C, Hortobagyi GN: Molecular predictors of response to trastuzumab and lapatinib in breast cancer. Nat Rev Clin Oncol. 2010, 7: 98-107. 10.1038/nrclinonc.2009.216.
Article
CAS
PubMed
Google Scholar
Alvarez RH, Valero V, Hortobagyi GN: Emerging targeted therapies for breast cancer. J Clin Oncol. 2010, 28: 3366-3379. 10.1200/JCO.2009.25.4011.
Article
CAS
PubMed
Google Scholar
Hurvitz SA, Hu Y, O'Brien N, Finn RS: Current approaches and future directions in the treatment of HER2-positive breast cancer. Canc Treat Rev. 2013, 39: 219-229. 10.1016/j.ctrv.2012.04.008.
Article
CAS
Google Scholar
Tripathy D, Slamon DJ, Cobleigh M, Arnold A, Saleh M, Mortimer JE, Murphy M, Stewart SJ: Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J Clin Oncol. 2004, 22: 1063-1070. 10.1200/JCO.2004.06.557.
Article
CAS
PubMed
Google Scholar
Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, Jagiello-Gruszfeld A, Crown J, Chan A, Kaufman B, Skarlos D, Campone M, Davidson N, Berger M, Oliva C, Rubin SD, Stein S, Cameron D: Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006, 355: 2733-2743. 10.1056/NEJMoa064320.
Article
CAS
PubMed
Google Scholar
von Minckwitz G, du Bois A, Schmidt M, Maass N, Cufer T, de Jongh FE, Maartense E, Zielinski C, Kaufmann M, Bauer W, Baumann KH, Clemens MR, Duerr R, Uleer C, Andersson M, Stein RC, Nekljudova V, Loibl S: Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a German Breast Group 26/Breast International Group 03–05 study. J Clin Oncol. 2009, 27: 1999-2006. 10.1200/JCO.2008.19.6618.
Article
CAS
PubMed
Google Scholar
Blackwell K, Burstein HJ, Storniolo AM, Rugo HS, Sledge G, Aktan G, Ellis C, Florance A, Vukelja S, Bischoff J, Baselga J, O'Shaughnessy J: Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 study. J Clin Oncol. 2012, 30: 2585-2592. 10.1200/JCO.2011.35.6725.
Article
CAS
PubMed
Google Scholar
Petrelli F, Barni S: A pooled analysis of 2618 patients treated with trastuzumab beyond progression for advanced breast cancer. Clin Breast Canc. 2013, 13: 81-87. 10.1016/j.clbc.2012.11.008.
Article
CAS
Google Scholar
Fabi A, Metro G, Ferretti G, Giannarelli D, Di Cosimo S, Papaldo P, Mottolese M, Carlini P, Felici A, Russillo M, Cognetti F: Do HER-2 positive metastatic breast cancer patients benefit from the use of trastuzumab beyond disease progression? A mono-institutional experience and systematic review of observational studies. Breast. 2008, 17: 499-505. 10.1016/j.breast.2008.03.006.
Article
PubMed
Google Scholar
Baselga J, Gelmon KA, Verma S, Wardley A, Conte P, Miles D, Bianchi G, Cortes J, McNally VA, Ross GA, Fumoleau P, Gianni L: Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol. 2010, 28: 1138-1144. 10.1200/JCO.2009.24.2024.
Article
CAS
PubMed
Google Scholar
Baselga J, Cortés J, Kim S-B, Im SA, Hegg R, Im YH, Roman L, Pedrini JL, Pienkowski T, Knott A, Clark E, Benyunes MC, Ross G, Swain SM, CLEOPATRA Study Group: Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012, 366: 109-119. 10.1056/NEJMoa1113216.
Article
CAS
PubMed
Google Scholar
Swain SM, Kim SB, Cortés J, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero JM, Schneeweiss A, Knott A, Clark E, Ross G, Benyunes MC, Baselga J: Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2013, 14: 461-471. 10.1016/S1470-2045(13)70130-X.
Article
CAS
PubMed
PubMed Central
Google Scholar
Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation. Cell. 2011, 144: 646-674. 10.1016/j.cell.2011.02.013.
Article
CAS
PubMed
Google Scholar
Brufsky AM, Mayer M, Rugo HS, Kaufman PA, Tan-Chiu E, Tripathy D, Tudor IC, Wang LI, Brammer MG, Shing M, Yood MU, Yardley DA: Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER. Clin Canc Res. 2011, 17: 4834-4843. 10.1158/1078-0432.CCR-10-2962.
Article
CAS
Google Scholar
Rugo H, Kaufman P, Tan-Chiu E, Ulcickas Yood M, Paik S, Yardley D, Brufsky A, Mayer M, Birkner M, Wang L, Brammer M, Tripathy D: Survival of patients with HER2+ metastatic breast cancer and use of trastuzumab following progression: analysis of RegistHER. Presented at: 31st Annual San Antonio Breast Cancer Symposium. 2008, San Antonio, TX, Abstract 3142
Google Scholar
Tripathy D, Kaufman PA, Brufsky AM, Mayer M, Yood MU, Yoo B, Qhah C, Yardley D, Rugo HS: First-line treatment patterns and clinical outcomes in patients with HER2-positive and hormone receptor-positive metastatic breast cancer from registHER. Oncologist. 2013, 18: 501-510. 10.1634/theoncologist.2012-0414.
Article
CAS
PubMed
PubMed Central
Google Scholar
Kaufman PA, Brufsky AM, Mayer M, Rugo HS, Tripathy D, Yood MU, Feng S, Wang LI, Quah CS, Yardley DA: Treatment patterns and clinical outcomes in elderly patients with HER2-positive metastatic breast cancer from the registHER observational study. Breast Canc Res Treat. 2012, 135: 875-883. 10.1007/s10549-012-2209-z.
Article
Google Scholar
Yardley DA, Kaufman PA, Brufsky A, Ulcickas Yood M, Rugo H, Mayer M, Quah C, Yoo B, Tripathy D: Treatment patterns and clinical outcomes for patients with de novo versus recurrent HER2-positive metastatic breast cancer. Breast Canc Res Treat. 2014, [Epub ahead of print]
Google Scholar
Yardley D, Tripathy D, Brufsky AM, Rugo HS, Kaufman PA, Mayer M, Magidson J, Yoo B, Quah C, Ulcickas Yood M: Long-term survivor characteristics in HER2-positive metastatic breast cancer from registHER. Br J Canc. 2014, doi:10.1038/bjc.2014.174. [Epub ahead of print]
Google Scholar
Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, Pegram M, Oh DY, Diéras V, Guardino E, Fang L, Lu MW, Olsen S, Blackwell K, the EMILIA Study Group: Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012, 367: 1783-1791. 10.1056/NEJMoa1209124.
Article
CAS
PubMed
Google Scholar
Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, Zelen M, Mandelblatt JS, Yakovlev AY, Habbema JD, Feuer EJ, Cancer Intervention and Surveillance Modeling Network (CISNET) Collaborators: Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005, 353: 1784-1792. 10.1056/NEJMoa050518.
Article
CAS
PubMed
Google Scholar
Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005, 353: 1673-1684. 10.1056/NEJMoa052122.
Article
CAS
PubMed
Google Scholar
Awada A, Bozovic-Spasojevic I, Chow L: New therapies in HER2-positive breast cancer: a major step towards a cure of the disease?. Canc Treat Rev. 2012, 38: 494-504. 10.1016/j.ctrv.2012.01.001.
Article
CAS
Google Scholar
National Cancer Institute Cancer Evaluation Program (CTEP): Common Terminology Criteria for Adverse events (CTCAE) and Common Toxicity Criteria (CTC). http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40,
Basch E, Abernethy AP, Mullins CD, Reeve BB, Smith ML, Coons SJ, Sloan J, Wenzel K, Chauhan C, Eppard W, Frank ES, Lipscomb J, Raymond SA, Spencer M, Tunis S: Recommendations for incorporating patient-reported outcomes into clinical comparative effectiveness research in adult oncology. J Clin Oncol. 2012, 30: 4249-4255. 10.1200/JCO.2012.42.5967.
Article
PubMed
Google Scholar
Brady MJ, Cella DF, Mo F, Bonomi AE, Tulsky DS, Lloyd SR, Deasy S, Cobleigh M, Shiomoto G: Reliability and validity of the functional assessment of cancer therapy-breast quality-of-life instrument. J Clin Oncol. 1997, 15: 974-986.
CAS
PubMed
Google Scholar
Hausheer FH, Schilsky RL, Bain S, Berghorn EJ, Lieberman F: Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Semin Oncol. 2006, 33: 15-49.
Article
CAS
PubMed
Google Scholar
Armstrong TS, Cohen M, Eriksen L, Cleeland C: Content validity of self-report measurement instruments: an illustration from the development of the brain tumor module of the M. D. Anderson symptom Inventory. Oncol Nurs Forum. 2005, 32: 669-676. 10.1188/05.ONF.669-676.
Article
PubMed
Google Scholar
De Haes JCJM, Olschewski M, Fayers P, Visser MRM, Cull A, Hopwood P, Sanderman R: The Rotterdam Symptom Checklist (RSCL): a manual. 1996, Groningen, the Netherlands: Northern Centre for Healthcare Research, http://www.rug.nl/research/share/,
Google Scholar
Reilly Associates Health Outcomes Research: Work Productivity and Activity Impairment Questionnaire (WPAI). http://www.reillyassociates.net/index.html,
Sharp L, Timmons A: National Cancer Registry/Irish Cancer Society 2010. The financial impact of a cancer diagnosis. 2010
Google Scholar
Wilcoxon F: Individual comparisons by ranking methods. Biom Bull. 1945, 1: 80-83. 10.2307/3001968.
Article
Google Scholar
Kruskal WH, Wallis WA: Use of ranks in one-criterion variance analysis. J Am Stat Assoc. 1952, 47: 583-621. 10.1080/01621459.1952.10483441.
Article
Google Scholar
Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958, 53: 457-481. 10.1080/01621459.1958.10501452.
Article
Google Scholar
Cox DR: Regression models and life-tables. J R Stat Soc Ser B. 1972, 34: 187-220.
Google Scholar
Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001, 344: 783-792. 10.1056/NEJM200103153441101.
Article
CAS
PubMed
Google Scholar
Lipscomb J, Reeve BB, Clauser SB, Abrams JS, Bruner DW, Burke LB, Denicoff AM, Ganz PA, Gondek K, Minasian LM, O'Mara AM, Revicki DA, Rock EP, Rowland JH, Sgambati M, Trimble EL: Patient-reported outcomes assessment in cancer trials: taking stock, moving forward. J Clin Oncol. 2007, 25: 5133-5140. 10.1200/JCO.2007.12.4644.
Article
PubMed
Google Scholar
Kaufman PA, Mayer M, Dreyer NA: Patient-reported outcomes (PRO) in patients with metastatic breast cancer (MBC) from the VIRGO observational cohort study (OCS) [abstract e11051]. J Clin Oncol. 2012, 30 (Suppl):
Basch E, Iasonos A, Barz A, Culkin A, Kris MG, Artz D, Fearn P, Speakman J, Farquhar R, Scher HI, McCabe M, Schrag D: Long-term toxicity monitoring via electronic patient-reported outcomes in patients receiving chemotherapy. J Clin Oncol. 2007, 25: 5374-5380. 10.1200/JCO.2007.11.2243.
Article
PubMed
Google Scholar
Eroglu Z, Tagawa T, Somlo G: Human epidermal growth factor receptor family-targeted therapies in the treatment of HER2-overexpressing breast cancer. Oncologist. 2014, 19: 135-150. 10.1634/theoncologist.2013-0283.
Article
CAS
PubMed
PubMed Central
Google Scholar